NEIL GESUNDHEIT, MD
Osteopathic Medicine at Pasteur Dr, Palo Alto, CA
License number
California G40267
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
300 Pasteur Dr, Palo Alto, CA 94305
Phone
(650) 497-8000
Organization information
See more information about NEIL GESUNDHEIT at bizstanding.comNeil Gesundheit MD,MPH
300 Pasteur Dr, Palo Alto, CA 94304
Industry:
Internist
Phone:
(650) 724-5454 (Phone)
Neil Gesundheit
Professional information
Dr. Neil Gesundheit, Stanford CA - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
300 Pasteur Dr, Stanford 94305
(650) 497-8000 (Phone)
STANFORD HOSPITAL AND CLINICS
250 Portola Ct, Los Altos 94022
(650) 941-3126 (Phone), (650) 325-2173 (Fax)
(650) 497-8000 (Phone)
STANFORD HOSPITAL AND CLINICS
250 Portola Ct, Los Altos 94022
(650) 941-3126 (Phone), (650) 325-2173 (Fax)
Certifications:
Diabetes, Metabolism & Endocrinology, 1985, Internal Medicine, 1981
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
300 Pasteur Dr, Stanford 94305
STANFORD HOSPITAL AND CLINICS
250 Portola Ct, Los Altos 94022
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
STANFORD HOSPITAL AND CLINICS
250 Portola Ct, Los Altos 94022
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Education:
Medical School
University of California At San Francisco
Graduated: 1978
Stanford Hospital
U Calif
Natl Inst Hlth
University of California At San Francisco
Graduated: 1978
Stanford Hospital
U Calif
Natl Inst Hlth
Method Of Administration Of Igf-I
US Patent:
5741776, Apr 21, 1998
Filed:
May 22, 1995
Appl. No.:
8/445805
Inventors:
Ross G. Clark - Pacifica CA
Neil Gesundheit - Palo Alto CA
Marc R. Hammerman - St. Louis MO
Steven B. Miller - St. Louis MO
Neil Gesundheit - Palo Alto CA
Marc R. Hammerman - St. Louis MO
Steven B. Miller - St. Louis MO
Assignee:
Genentech, Inc. - South San Francisco CA
Washington University - St. Louis MO
Washington University - St. Louis MO
International Classification:
A61K 3800, A61K 3827
US Classification:
514 12
Abstract:
A method is disclosed that comprises administering insulin-like growth factor-I (IGF-I) to a mammal so as to sustain its biological activity in the mammal comprising administering a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for a period of time that stimulates the maximum biological response in the mammal, then discontinuing said administration for a period of time equal to or less than the time period used for administration, and repeating this pattern of administration and discontinuance of administration for a period as long as necessary to achieve or maintain the desired biological response in the mammal.
Method Of Administration Of Igf-I
US Patent:
5565428, Oct 15, 1996
Filed:
May 22, 1995
Appl. No.:
8/447292
Inventors:
Ross G. Clark - Pacifica CA
Neil Gesundheit - Palo Alto CA
Marc R. Hammerman - St. Louis MO
Steven B. Miller - St. Louis MO
Neil Gesundheit - Palo Alto CA
Marc R. Hammerman - St. Louis MO
Steven B. Miller - St. Louis MO
Assignee:
Genentech, Inc. - South San Francisco CA
Washington University - St. Louis MO
Washington University - St. Louis MO
International Classification:
A61K 3800, A61K 3827
US Classification:
514 12
Abstract:
A method is disclosed that comprises administering insulin-like growth factor-I (IGF-I) to a mammal so as to sustain its biological activity in the mammal comprising administering a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for a period of time that stimulates the maximum biological response in the mammal, then discontinuing said administration for a period of time equal to or less than the time period used for administration, and repeating this pattern of administration and discontinuance of administration for a period as long as necessary to achieve or maintain the desired biological response in the mammal.